Manual Review Required

KRAS G12C

solid tumor basket · Therapy Not Normalized

KRAS G12C is flagged as manual review required because public trials show inclusion required evidence in 14 contexts. FDA CDx context should be reviewed manually.

Back to report

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 11

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 13

Common snippets: KRAS G12C | KRAS G12C | KRAS G12C

Threshold label: Moderate

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: Low

Patent-density signal

Diagnostic appendix

Signal count: 1

Recent signals: 1

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT03118817 | https://clinicaltrials.gov/study/NCT06944457 | https://clinicaltrials.gov/study/NCT06237400 | https://clinicaltrials.gov/study/NCT05768321 | https://clinicaltrials.gov/study/NCT06117371 | https://clinicaltrials.gov/study/NCT06235983 | https://clinicaltrials.gov/study/NCT06243354 | https://clinicaltrials.gov/study/NCT06383871 | https://clinicaltrials.gov/study/NCT04380753 | https://clinicaltrials.gov/study/NCT06435455 | https://clinicaltrials.gov/study/NCT05263986 | https://clinicaltrials.gov/study/NCT05010694 | https://clinicaltrials.gov/study/NCT06006793 | https://clinicaltrials.gov/study/NCT05707676